Viatris Reports Strong Q1 Adjusted EPS and Revenue Growth, Details Major Restructuring and Operational Challenges

summarizeSummary

Viatris reported strong Q1 2026 adjusted earnings and revenue growth, with GAAP net earnings turning positive. The company detailed a major restructuring program, operational setbacks from a facility fire and FDA issues, and the completion of a significant divestiture, alongside mixed litigation outcomes.

check_boxKey Events

• Strong Q1 Financial Performance

  Reported adjusted diluted EPS of $0.59, exceeding prior year's $0.50, and an 8% increase in total revenues to $3.52 billion. GAAP net earnings turned positive to $176.4 million, compared to a $3.04 billion loss in Q1 2025, largely due to the absence of a significant goodwill impairment charge from the prior year.

• Major Restructuring Program Underway

  Initiated a 2026 restructuring program involving a global workforce reduction of up to 10%, with expected pre-tax charges of $700 million to $850 million. $77.9 million in charges were recognized in Q1 2026.

• Operational Challenges at Manufacturing Facilities

  Incurred $71.9 million in charges due to a fire at the Nashik, India facility, with full operations expected to resume by July 2026. The Indore, India facility continues to face an FDA warning letter and import alert for 11 products destined for the U.S. market.

• Biocon Biologics Divestiture Completed

  Finalized the sale of its equity stake in Biocon Biologics in Q1 2026 for $815.0 million, including $400.0 million in cash, enhancing the company's liquidity.

auto_awesomeAnalysis

Viatris Inc. filed its Q1 2026 10-Q, confirming strong adjusted financial results previously announced, with adjusted diluted EPS of $0.59, surpassing the prior year's $0.50, and total revenues increasing 8% to $3.52 billion. Notably, GAAP net earnings turned positive to $176.4 million, a significant improvement from a $3.04 billion loss in Q1 2025, primarily due to the absence of a $2.94 billion goodwill impairment charge recorded in the prior year. The company is actively implementing a 2026 restructuring program, which includes a global workforce reduction of up to 10% and is expected to incur total pre-tax charges between $700 million and $850 million, with $77.9 million recognized in Q1. Operational challenges include a $71.9 million charge related to a fire at its Nashik manufacturing facility, which is expected to resume full operations by July 2026, and an ongoing FDA import alert for 11 products from its Indore facility. The completion of the Biocon Biologics divestiture in Q1 2026 generated $815.0 million in consideration, including $400.0 million in cash, enhancing liquidity. Litigation updates are mixed, with a positive dismissal of the Perindopril case for lack of jurisdiction, but a negative denial of a preliminary injunction for Amitiza in Japan, which the company is appealing. The stock is currently trading near its 52-week high, reflecting market optimism around its adjusted earnings performance and strategic actions, despite the operational headwinds and ongoing restructuring costs.